search
Back to results

Effects of Peanut and Peanut Butter Consumption on Blood Lipids and Glycemic Control in Adults With Type 2 Diabetes

Primary Purpose

Type 2 Diabetes

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Peanuts and peanut butter
Sponsored by
Loma Linda University
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes focused on measuring diabetes, cholesterol, peanuts, peanut butter, dietary intervention, HDL cholesterol

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Presence of a medical diagnosis of diabetes for at least 6 months
  • HbA1c < 9%
  • Age greater than 18 years
  • Resident of Loma Linda, California area

Exclusion Criteria:

  • Allergy to peanuts
  • Smokers
  • History of irritable bowel disease or diverticulitis
  • Statin therapy (unless stable statin dose for 3 months)

Sites / Locations

  • Loma Linda University Medical Center Diabetes Treatment Center

Outcomes

Primary Outcome Measures

The primary outcome measure is HDL-C

Secondary Outcome Measures

Serum lipids, glucose, HbA1c, anthropometrics and blood pressure

Full Information

First Posted
July 8, 2009
Last Updated
June 19, 2012
Sponsor
Loma Linda University
Collaborators
National Peanut Board
search

1. Study Identification

Unique Protocol Identification Number
NCT00937222
Brief Title
Effects of Peanut and Peanut Butter Consumption on Blood Lipids and Glycemic Control in Adults With Type 2 Diabetes
Official Title
Effects of Peanut and Peanut Butter Consumption on Blood Lipids and Glycemic Control in Adults Ith Type 2 Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
June 2012
Overall Recruitment Status
Completed
Study Start Date
June 2009 (undefined)
Primary Completion Date
October 2011 (Actual)
Study Completion Date
October 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Loma Linda University
Collaborators
National Peanut Board

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Peanuts and peanut butter contain high levels of monounsaturated fat (MUFA), arginine, fiber, phytosterols, resveratrol and vitamin E that have the potential to reduce cardiovascular disease (CVD) risk through improved blood glucose control and favorable modification of blood lipids. When substituted for saturated fat in the diet, MUFA may have important metabolic benefits for persons with diabetes. Therefore, the investigators propose to study the effects of a peanut and peanut butter-enriched diet on markers of CVD risk factors in free-living adults with diabetes residing in Southern California. This study's primary clinical outcome will be high-density lipoprotein (HDL) - cholesterol. Secondary outcomes will include additional serum lipids (total cholesterol, low-density lipoprotein (LDL) - cholesterol and triacylglycerol), glucose, HbA1c, and anthropometry (body weight, body composition and waist circumference). This study will provide vital information about the role of peanuts and peanut butter in modulating blood glucose homeostasis and CVD risk factors among adults with diabetes.
Detailed Description
This will be a parallel randomized controlled intervention study on free-living adults with diabetes. The study duration will be 6 months. Participants will be randomized to receive one of two dietary approaches (moderate fat, control; and, moderate fat inclusive of 32 g peanuts or 2 Tbsp. peanut butter per day, intervention) to an ADA meal plan targeting a profile of 35% fat, 45% CHO and 20% protein. A supply of peanuts and peanut butter from the National Peanut Board will be provided to participants assigned to the intervention group at clinic visits. The peanuts and peanut butter will be consumed as part of the participant's customary meals and snacks. In light of ADA's prior recommendation to derive 60 to 70% of energy intake from CHO and MUFA, the peanuts and peanut butter will provide an enhanced proportion of energy from MUFA (total fat content of peanuts by compositional weight is 22% and 52% of the total fat is MUFA). An experienced Registered Dietitian and Certified Diabetes Educator will oversee the dietary advice provided to each of the two groups. All participants will be provided with an individualized portion-controlled meal plan using the ADA food exchange lists and possibly modified fat instruction on fatty acid considerations and inclusion of peanuts and peanut butter. Dietary compliance, especially the intake of peanuts and peanut butter, will be measured by six 24-hour recalls without notice (telephone interview by a dietitian on what was consumed the previous day). Participants will be requested to maintain their activities and other lifestyle habits and to record in diaries provided to them any signs of illness, medications used, and any deviation from their prescribed diet. The investigators will examine diaries at the clinic visits. No major deviations from the protocol will be tolerated. Less than 100 ml of blood will be drawn from each participant at baseline (week 0), week 12 and week 24. All blood drawings will be performed at Loma Linda University Medical Center. Participants will report to the laboratory on the assigned days after fasting for a minimum of 12 hours. Body weight and body composition measurements (percent body fat, fat free mass, total body water) will be obtained at each clinic visit using an internally calibrated segmental bioelectrical impedance analysis device (Tanita®, Arlington Heights, IL).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
Keywords
diabetes, cholesterol, peanuts, peanut butter, dietary intervention, HDL cholesterol

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
60 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Dietary Supplement
Intervention Name(s)
Peanuts and peanut butter
Intervention Description
Peanuts and peanut butter
Primary Outcome Measure Information:
Title
The primary outcome measure is HDL-C
Time Frame
12 weeks and 24 weeks
Secondary Outcome Measure Information:
Title
Serum lipids, glucose, HbA1c, anthropometrics and blood pressure
Time Frame
12 weeks and 24 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Presence of a medical diagnosis of diabetes for at least 6 months HbA1c < 9% Age greater than 18 years Resident of Loma Linda, California area Exclusion Criteria: Allergy to peanuts Smokers History of irritable bowel disease or diverticulitis Statin therapy (unless stable statin dose for 3 months)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Joan Sabaté, MD, DrPh
Organizational Affiliation
Chair, Department of Nutrition
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Michelle Wien, DrPH
Organizational Affiliation
Assistant Professor, Department of Nutrition
Official's Role
Study Director
Facility Information:
Facility Name
Loma Linda University Medical Center Diabetes Treatment Center
City
Loma Linda
State/Province
California
ZIP/Postal Code
92350
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
24450471
Citation
Wien M, Oda K, Sabate J. A randomized controlled trial to evaluate the effect of incorporating peanuts into an American Diabetes Association meal plan on the nutrient profile of the total diet and cardiometabolic parameters of adults with type 2 diabetes. Nutr J. 2014 Jan 22;13:10. doi: 10.1186/1475-2891-13-10.
Results Reference
derived
Links:
URL
http://www.nutstudies.org/currentstudies.html
Description
Related Info

Learn more about this trial

Effects of Peanut and Peanut Butter Consumption on Blood Lipids and Glycemic Control in Adults With Type 2 Diabetes

We'll reach out to this number within 24 hrs